CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia

M Mark B. Geyer (Memorial Sloan Kettering Cancer Center) S Susan DeWolf X Xiaoli Mi (2Department of Medicine, Cell Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY) K Kenyon Weis (3Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY) B Brian C. Shaffer (1Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY) B Briana Cadzin (Memorial Sloan Kettering Cancer Center, New York, New York, United States) D Devin McAvoy (Sloan Kettering Institute, New York, New York, United States) Z Zoe Katsamakis (4Department of Medicine, Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY) R Rachel Lorenc (7Pharmacology Program, Graduate School of Medical Sciences, Weill Cornell Medical College, New York, NY) A Alexander M. Lewis (3Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY) B Brianna Gipson M M. Adriana Cuibus (3Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY) N Narina N. Girotra (3Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY) K Kenton Wu (4Department of Medicine, Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY) N Natalie Smith E Erin R. Burns (1Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY) J Jasmine S. Um (1Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY) S Sarah Yoo (1Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY) B Behzad Kharabi Masouleh (8Tigen Pharma, Lausanne, Switzerland) P Pallavi Galera (9Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY) K Kinga Hosszu (Memorial Sloan Kettering Cancer Center, New York, New York, United States) J Jagrutiben Chaudhari (Memorial Sloan Kettering Cancer Center, New York, New York, United States) X Xiuyan Wang Q Qianqian Lin K Kevin J. Curran J Jae H. Park D David A. Scheinberg M Marcel R. M. van den Brink O Omar Abdel-Wahab (Molecular Pharmacology Program, Sloan Kettering Institute) R Renier J. Brentjens (Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States) A Anthony F. Daniyan (1Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY)

Abstract

Abstract Success of chimeric antigen receptor (CAR) T-cell therapy in lymphoid malignancies has not yet been recapitulated in acute myeloid leukemia (AML). We developed CAR T cells targeting CD371 with a mutated CD28 costimulatory domain to limit T-cell exhaustion, and constitutive interleukin-18 (IL-18) secretion to enhance immune function (CD371/SAVVY/IL-18 CAR). We initiated a phase 1 trial (NCT06017258), successfully manufactured and administered CD371/SAVVY/IL-18 CAR T cells in 5 patients with relapsed/refractory AML and observed expansion following a single infusion of 3 × 104 or 3 × 105 CAR T cells per kg; 3 patients refractory to ≥5 lines of therapy and postallogeneic transplant exhibited AML clearance and no evidence of graft-versus-host disease. Dose-limiting toxicity in the 2 patients treated with 3 × 105 CAR T cells per kg dose (prolonged cytopenias with marrow hypoplasia; severe cytokine release syndrome) led to dose reduction to 3 × 104 CAR T cells per kg in the following 3 patients. Single-cell analyses revealed that circulating CAR T cells in responders included predominantly cytotoxic CD8+ effector T cells 2 weeks after infusion while coexisting natural killer (NK) cells expressed markers of activation. This pilot study highlights the activity of low-dose IL-18 “armored” CAR T cells against refractory AML and their potential to promote CAR T-cell cytotoxicity and innate endogenous antitumor immunity. This trial was registered at www.ClinicalTrials.gov as #NCT06017258.

Article Details

Journal Blood
Volume / Issue Vol. 146, Issue 26
Published December 25, 2025
Pages 3163-3174
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (31)

M

Mark B. Geyer

Memorial Sloan Kettering Cancer Center

S

Susan DeWolf

X

Xiaoli Mi

2Department of Medicine, Cell Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY

K

Kenyon Weis

3Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY

B

Brian C. Shaffer

1Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY

B

Briana Cadzin

Memorial Sloan Kettering Cancer Center, New York, New York, United States

D

Devin McAvoy

Sloan Kettering Institute, New York, New York, United States

Z

Zoe Katsamakis

4Department of Medicine, Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY

R

Rachel Lorenc

7Pharmacology Program, Graduate School of Medical Sciences, Weill Cornell Medical College, New York, NY

A

Alexander M. Lewis

3Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY

B

Brianna Gipson

M

M. Adriana Cuibus

3Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY

N

Narina N. Girotra

3Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY

K

Kenton Wu

4Department of Medicine, Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY

N

Natalie Smith

E

Erin R. Burns

1Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

J

Jasmine S. Um

1Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

S

Sarah Yoo

1Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

B

Behzad Kharabi Masouleh

8Tigen Pharma, Lausanne, Switzerland

P

Pallavi Galera

9Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

K

Kinga Hosszu

Memorial Sloan Kettering Cancer Center, New York, New York, United States

J

Jagrutiben Chaudhari

Memorial Sloan Kettering Cancer Center, New York, New York, United States

X

Xiuyan Wang

Q

Qianqian Lin

K

Kevin J. Curran

J

Jae H. Park

D

David A. Scheinberg

M

Marcel R. M. van den Brink

O

Omar Abdel-Wahab

Molecular Pharmacology Program, Sloan Kettering Institute

R

Renier J. Brentjens

Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

A

Anthony F. Daniyan

1Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY